ScreenerHero

LCTX Lineage Cell Therapeutics, Inc.

AMEX · US · Healthcare · Biotechnology · lineagecell.com
0.9476USD+1.03%Mkt Cap: 239.66M $P/E: —

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap239.66M USD
Enterprise Value187.55M USD
Revenue (TTM)13.08M USD
Gross Profit14.41M USD
Net Income (TTM)-63.53M USD
Revenue/Share0.05 USD
Last Price0.9476 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees72
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.82
PEG10.64
EV/EBITDA-7.18
EV/Revenue14.34
P/S18.13
P/B3.89
EPS (TTM)-0.19
EPS (Forward)-0.14
52W Range
0.88235% of range2.090
52W High2.090 USD
52W Low0.8823 USD
Profitability
Gross Margin99.00%
Oper. Margin-834.70%
EBITDA Margin-199.58%
Profit Margin-436.47%
ROE-142.61%
ROA-56.43%
Growth
Revenue Growth-61.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.92M USD
CapEx (TTM)522.00K USD
FCF Margin-112.93%
FCF Yield-6.16%
Net Debt-48.53M USD
Net Debt/EBITDA1.86
Balance Sheet
Debt/Equity0.05
Current Ratio6.61
Quick Ratio6.46
Book Value/Sh0.24 USD
Cash/Share0.20 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split3:1
Split DateOct 31, 1997
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.500 USD
Upside (mean)+480.4%
Target Range3.000 USD – 9.000 USD
3.000+480.4% to mean9.000
# Analysts6
Ownership
Shares Out.252.91M
Float190.90M
Insiders4.86%
Institutions48.22%
Short Interest
Short Ratio29.9d
Short % Float19.33%
Short % Out.11.65%
Shares Short29.47M
Short (prev mo.)28.33M
Technical
SMA 501.057 (-10.3%)
SMA 2001.391 (-31.9%)
Beta1.60
S&P 52W Chg15.77%
Avg Vol (30d)1.25M
Avg Vol (10d)1.82M
Technical Indicators
RSI (14)40.1
MACD-0.0468
MACD Signal-0.0440
MACD Hist.-0.0028
BB Upper1.149 USD
BB Middle1.007 USD
BB Lower0.8654 USD
BB Width28.17%
ATR (14)0.0627 USD
Vol Ratio (20d)1.03x